AstraZeneca expands deal with ImaginAb; Ovid posts promising data on Takeda-partnered seizure drug
→ On a day when AstraZeneca issued a flurry of updates on three of its blockbuster therapies, the British drugmaker also expanded its deal with ImaginAb, an immuno-oncology imaging company. The partnership gives AstraZeneca access to ImaginAb’s CD8 ImmunoPET technology, which is a diagnostic approach used to non-invasively measure the effect of immunotherapies. The financial details of the deal were not disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.